Metabolic and Mendelian Disorders

Sidra Medicine’s Metabolic and Mendelian Disorders Program, known as Genome 2 Cure (G2C), represents a groundbreaking endeavor designed specifically to address the distinct healthcare requirements of the Qatari population. Its goal is to revolutionize medical practice and improve the well-being of individuals grappling with metabolic disorders, while also serving as a catchment for other Mendelian and rare conditions not addressed by existing programs, ultimately enhancing patient outcomes. The following are the Gold Cohorts recruited in this program:

• Newborn sequencing for screening
• Type I Diabetes
• Mendelian disorders not captured by other programs